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 Summary 
Purpose: The association between autism spectrum disorders (ASD) and prenatal 
anticonvulsant exposure is increasingly investigated, but comprehensive, blinded 
assessment using a validated instrument for autism within a well-characterised 
prospective cohort has not been conducted. Thus, existing studies may represent an 
underestimate of the true risk. Here we present a prospective cohort study in children 
exposed to anticonvulsants during pregnancy, with all assessments conducted blind to 
drug exposure status.  
Methods: Participants were 105 Australian children aged 6-8 years who were recruited 
via the Australian Pregnancy Register for Women on Antiepileptic Medication. Maternal 
epilepsy, pregnancy and medical history data were obtained prospectively. Autism traits 
were assessed using the Childhood Autism Rating Scale (CARS).  
Key findings: Eleven children (10.5%) had elevated CARS scores. Two were exposed to 
valproate monotherapy (2/26; 7.7%), two to carbamazepine monotherapy (2/34; 5.9%) 
and seven to valproate in polytherapy (7/15; 46.7%). Linear regression analysis showed 
that the mean valproate dose during pregnancy was a significant predictor of CARS 
scores after controlling for polytherapy, mean carbamazepine dose, folic acid use, 
seizures during pregnancy, tobacco and marijuana use, maternal IQ and socioeconomic 
status. First trimester folic acid supplementation and marijuana use were also significant 
predictors of CARS scores.  
Significance: Using direct assessment of children in our prospective study, we found an 
elevated rate of autism traits across the sample. The most important determinant of 
association with autistic traits was higher doses of sodium valproate exposure. The use of 
valproate in women who may become pregnant is now generally avoided, however there 
are insufficient data regarding the risk of ASD with low-dose valproate. If this risk is no 
greater than other AEDs, it may enable women with genetic generalised epilepsy to retain 
optimal seizure control as well as minimize harm to their unborn child.   
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Introduction 
Antiepileptic drugs (AEDs) are a group of commonly prescribed medications used to treat 
epilepsy, bipolar depression and severe pain. Fetal exposure to AEDs is known to 
increase the risk of congenital malformations and intellectual impairment1-3. Sodium 
valproate appears to carry a heightened risk, particularly at higher doses4; 5. Early 
concerns about a possible link between fetal exposure to AEDs and neurobehavioural 
problems, specifically autism spectrum disorders (ASD) arose from case report, 
retrospective and animal studies6-10. More recently, Bromley and colleagues11 found an 
increased rate of ASD amongst children exposed prenatally to AEDs, with seven (2.8%) 
of the 249 AED-exposed children in their sample receiving diagnoses independently of 
the study11.  The majority were exposed to valproate monotherapy (6.3% of the group 
exposed to valproate monotherapy) or valproate in combination with other AEDs. Of note, 
however, this paper reported cases for whom a diagnosis was made separately to the 
study, by the child’s health-care professional; no formal assessment was undertaken as 
part of the study protocol. It is therefore likely that the incidence of ASD was 
underestimated. Nevertheless, their findings were echoed in a data-linkage study12 which 
reported an absolute risk of 4.15% for ASD and 2.95% absolute risk for childhood autism 
in children exposed to sodium valproate compared to all children of women with epilepsy. 
The Norwegian Mother and Baby Cohort also found an elevated risk of autistic traits in 
children exposed to AEDs using maternal assessments of the child at three years of age 
(6.0% across all exposures compared to a reference rate of 1.5%). They found 
significantly elevated rates in children exposed to monotherapy (5.6%) but not 
polytherapy, and this reflected a particular increase in children exposed to lamotrigine 
(9%) but not valproate or carbamazepine13. The lack of dose information in the latter 
study prevents further interrogation of the pattern of results for valproate, which differs 
from previous studies.  
No study to date has conducted blind assessment of autism traits using a validated 
instrument in a cohort of children exposed to AEDs in whom prospectively collected data 
on pregnancy and epilepsy variables are available. A better understanding of the 
incidence of ASD in children who have had prenatal AED exposure is important for 
clinical management of women with epilepsy and their families. A lack of systematic 
assessment or control for confounding variables may lead to either under- or over-
estimation of the true incidence of ASD associated with prenatal AED exposure. This in 
turn has direct implications for the management of women with epilepsy. The aim of the 
current study was to systematically investigate rates of ASD, using objective 
assessments in a prospectively-recruited AED-exposed sample. We adopted a pragmatic 
approach that used a reliable screening tool rather than extended assessment, given our 
broader study protocol. We predicted that children prenatally exposed to AEDs, 
particularly valproate, would exhibit elevated rates of ASD in comparison to the general 
population, which is similar in our Australian setting (0.63%14) to global estimates 
(0.62%)15. 
 
Methods 
Participants: Women with epilepsy and their children were recruited through the 
Australian Pregnancy Register for Women on Antiepileptic Medication (APR)4. The APR 
commenced prospective data collection about AED use by pregnant women in 1999. The 
register is voluntary, and women across all Australian states and territories are eligible to 
participate; all contact is by telephone. A variety of methods are used to inform women 
about the register, including by their treating medical practitioners, nurses, or allied health 
professionals, or by other pregnant women and national advertising (website, lay 
organisations for epilepsy). Following written informed consent, relevant details are 
obtained from pregnant women on recruitment (usually in the first or second trimester), at 
7 months of pregnancy, in the first postnatal month, and at the end of the first postnatal 
year. Treating doctors are contacted to confirm medical details. Fetal malformations are 
classified according to the Birth Defects Registry of Victoria 16. Children with major birth 
defects or a diagnosis of epilepsy were excluded, as these conditions are known risk 
factors for ASD17; 18.   
Between November 2007 and May 2010, 175 women with 190 children aged six to eight 
years were identified from the APR and invited to participate in the study. Mothers of 27 
children (14%) declined to participate. The most common reasons for non-participation 
were concerns about their child’s ability to cope with testing (33%), inability to meet the 
time commitment (26%), and maternal illness (11%). Mothers of two children were 
deceased, and two had moved overseas or to inaccessible areas of Australia. Mothers of 
a further 48 children expressed interest in the study but were not seen because an 
appointment was unable to be scheduled during the study period. Of the remaining 111 
children (including two sets of twins), six were excluded; two had developed epilepsy, two 
had malformations detected after one year of age, and two were not exposed to AEDs. 
The remaining 105 children comprised 26 who were exposed in utero to sodium 
valproate, 34 to carbamazepine, 11 to other AEDs in monotherapy and 34 to AED 
polytherapy. Demographic details of participating families are provided in Table 1. For 
women taking polytherapy, the combination of drugs for those taking valproate (N=15) 
and those who did not (N=19) is shown in Table 2. The mean age of assessment was 7.4 
years (SD=0.6 years).  
 [INSERT TABLE 1 ABOUT HERE] 
[INSERT TABLE 2 ABOUT HERE] 
 
There was no significant difference between mothers of the children reported here, and 
those who did not participate in maternal age, frequency of drug type, or frequency of 
epilepsy type. The mean gestational age of children born to mothers who did not agree to 
participate (38.53, SD=2.79 weeks) was significantly lower than those who did participate 
(39.35; SD=1.78 weeks), and this was due to a significantly higher proportion of preterm 
births in the non-participatory group (χ2=8.9, p=.003).  
Procedures: Maternal epilepsy, pregnancy and medical history data were obtained from 
prospectively-collected records. Maternal and paternal demographic data were collected, 
and maternal IQ was measured with the Wechsler Abbreviated Scale of Intelligence19. 
Family socioeconomic status (SES), as measured by the highest maternal or paternal 
occupational level, was rated according to the ANU4 Scale20. Dichotomous variables 
were created for maternal polytherapy, folic acid and marijuana use, and the presence or 
absence of seizures during pregancy. Children participated in a neuropsychological 
examination, including assessment with the Childhood Autism Rating Scale (CARS)21. All 
assessments were conducted blind to drug exposure status of the child and clinical 
diagnosis of the mother. Assessments with the Childhood Autism Rating Scale (CARS) 
were conducted by two authors (CN, SB) and consensus meetings conducted (CN, SB, 
AW) to confirm scoring.  
The CARS is a commonly used clinician-rated behaviour observation scale. Scores range 
from 15 to 60, with scores of 30 or higher consistent with a diagnosis of autism. Scores 
above 27 also raise concern; children with Pervasive Development Disorder Not 
Otherwise Specified (PDD-NOS) have been reported to achieve mean CARS scores of 
28.3 ± 4.222. The CARS demonstrates good reliability and a high degree of correlation 
with DSM-IV diagnoses21-23; the relationship with DSM-V has not been reported to date. 
However, recent research found that CARS diagnoses correspond well with clinician 
diagnoses and the Autism Diagnostic Observation Schedule (ADOS)24 and the Autism 
Diagnostic Instrument-Revised25 and importantly the CARS was developed to 
differentiate ASD from other neurodevelopmental conditions, particularly intellectual 
disability. In the current paper, we use the term ‘autistic traits’ to refer to any child whose 
score on the CARS was equal to, or exceeded, 27 points. The ethics review boards of the 
coordinating institutions approved the study, and informed written consent was obtained 
from all women before participation. 
Statistical Analyses: Group statistics were calculated using Chi-square analysis for 
frequency data. Analysis of variance was used to compare scores across drug-exposure 
groups. Due to unequal group sizes, Mann-Whitney U was used to compare relevant 
scores in those with and without elevated CARS scores. Linear regression was used to 
examine the contribution of relevant variables (i.e. those identified in univariate analyses 
or based on findings in previous research) to outcomes of interest.  
Role of the funding source 
The sponsors of the study had no role in study design, data collection, data analysis, data 
interpretation, the writing of the report, or in the decision to submit the paper for 
publication. The corresponding author had full access to all the data in the study and had 
final responsibility for the decision to submit for publication. 
 
Results 
Of the 105 children exposed to AEDs in utero, 11 children met the criteria for autistic 
traits. Of these, eight children obtained scores higher than 30 on the CARS (placing them 
in the ‘autistic’ range), and another three displayed CARS scores over 27 (i.e. on the 
‘concern for autism’ range). Four of these children (3.8% of the total sample) had a 
previous diagnosis of ASD. One further child, exposed to valproate monotherapy, came 
to the study with an existing diagnosis of autistic traits, yet his high level of intellectual 
and language abilities placed him below the CARS cutoff, and he is not included in the 
analyses presented here. Two of the 11 affected children (7 boys, 4 girls) were exposed 
to valproate monotherapy, two to carbamazepine monotherapy and seven to valproate in 
combination with one or more other drugs. Details are provided in Tables 3 and 4.  
 
[INSERT TABLE 3 ABOUT HERE] 
 
Group comparisons showed that, compared to mothers of children without autistic traits, 
mothers of children with autistic traits were more likely to have had one or more seizures 
during pregnancy (p=.010, Fisher’s exact test), more likely to have used marijuana during 
pregnancy (p=.028, Fisher’s exact test), and less likely to have taken folic acid 
supplements in the first trimester (p=.028, Fisher’s exact test). Maternal IQ and family 
SES were also lower in the autistic traits group, but these differences were not 
statistically significant (Maternal IQ U=670.5, p=0.11; SES U=653.5, p=0.084). 
Nevertheless, given the known association in the general population between these 
variables and child IQ26 27 and the importance of these variables for long-term outcomes 
in children born to women with epilepsy3, these variables were retained for regression 
analyses. No group differences were found with regards to alcohol, tobacco, caffeine, or 
other drug use during pregnancy, preconception folic acid, parental age, or paternal 
education, epilepsy type, length of breastfeeding, pregnancy complications, birth type, 
anaesthetic use, or number of children born prematurely. 
 
 [INSERT TABLE 4 ABOUT HERE] 
 
CARS scores of children exposed to valproate (N = 26), carbamazepine (N = 34), 
lamotrigine (N = 9), polytherapy with valproate (N = 15) or polytherapy without valproate 
(N = 19) were compared. Specific details of the combination of medications used by 
women in the latter two groups are shown in Table 2. Children exposed to polytherapy 
with valproate scored significantly higher than all other groups, (mean difference = 7.55-
9.42, p<.001). No other group differences were significant. Mean scores for each group 
are shown in Figure 1.  
Repeated measures analysis of variance showed that the dose of valproate did not 
change significantly across pregnancy in the monotherapy (using the Huynh-Feldt 
correction for non-sphericity; F(1.6, 40.4)=3.14, p > 0.05) or polytherapy groups 
(corrected F(1.1,16.1)= 1.33, p>0.05). Thus, mean dose of valproate across pregnancy 
was used to examine the relationship with CARS scores across all participants exposed 
to valproate. This was, however, not significant (r=0.30, p=0.06, two-tailed). Mean dose of 
valproate was significantly higher in polytherapy (Mean = 1589, SD=986.66) versus 
monotherapy (Mean=961.78, SD=629.74) exposures (t(20.7)=-2.22, p = 0.04). Despite 
this, there was no relationship between CARS scores and VPA dose within the valproate 
polytherapy group (r=-.06, p> 0.1), but the association between dose and CARS scores 
was significant in those exposed only to valproate (r=0.61, p=0.001). There was no 
significant difference between the overall mean carbamazepine dose in the monotherapy 
(Mean=723.02, SD=447.86) and ‘other’ polytherapy groups (Mean=917.15, SD=315.98), 
t(46)=1.47, p > 0.05.  
Carbamazepine doses did increase significantly across pregnancy within the 
monotherapy group (corrected F(1.5,48.5)=5.00, p=0.018). Nevertheless, CARS scores 
were not significantly related to dose in the first, second or third trimester (all p  > 0.1).  
 
 [INSERT FIGURE 1 ABOUT HERE] 
 
Linear regression analysis (Table 5; adjusted R2 = 0.42, F (8, 92) = 9.95, p < .001) 
showed that mean valproate dose significantly predicted CARS scores after controlling 
for polytherapy, mean carbamazepine dose, folic acid use, tobacco and marijuana use, 
seizures during pregnancy, maternal IQ and SES. Use of folic acid in the first trimester 
and marijuana use were also significant predictors of CARS scores. The overall model 
and specific predictors remained unchanged when either of the siblings with elevated 
CARS scores was removed from the analysis. The regression analysis was repeated with 
valproate and carbamazepine exposure included as binary variables (i.e. not dose 
variables), and the overall model and the specific predictors remained significant.  
 
 
Discussion 
Here we report the first direct, prospective evaluation of autistic traits in a cohort of 
children exposed to AEDs in utero. In addition to children who had an existing ASD 
diagnosis when they entered the study, we identified another group whose CARS scores 
show they have autistic traits that warrant clinical investigation and support, 
demonstrating the importance of long-term follow up in children whose mothers required 
AEDs during pregnancy. The overall proportion of affected children in our sample is 
substantially higher than the estimated prevalence of ASD in six to twelve year-olds 
nationally or internationally. Children who had in-utero exposure to valproate were most 
likely to have elevated CARS scores, with 7.7% of the valproate monotherapy group and 
46.7% of the valproate polytherapy group displaying ASD symptoms. The dose of 
valproate taken during pregnancy was found to be an independent risk factor for elevated 
CARS scores, while polytherapy per se was not. CARS scores were not elevated in 
children exposed to polytherapy without valproate suggesting that valproate, or valproate 
dose, rather than polytherapy per se is the critical determinant of the relationship, an 
observation that requires verification in future studies. The observation of a dose-
response relationship within those exposed to valproate in monotherapy suggests a role 
for valproate in ASD risk. This finding  is in line with studies investigating the risk of other 
adverse outcomes (i.e. birth defects and neurocognitive deficits) in children who have had 
prenatal valproate exposure, which have also been found to have a strong relationship to 
dose1; 5; 28-32, with higher dose associated with poorer outcomes than low dose. There is 
not, however, a single agreed boundary at which ‘low’ versus ‘high’ is drawn. Recent data 
from the UK long-term follow-up study highlighted concern about verbal abilities and 
educational needs in children exposed to low-dose valproate 33, which could suggest that 
there is no ‘safe’ dose for valproate. This group is an important one, clinically, and 
additional neurodevelopmental research is required to clarify the consequences of low-
dose valproate exposure on the unborn child.  
 
There is not currently strong evidence for neurodevelopmental risk associated with 
intrauterine exposure carbamazepine. Recent data found subtle risks associated with this 
AED34, however the Cochrane consortium suggested recently that any association 
between poor outcome in younger children exposed to carbamazepine was lost when 
variability in studies was taken into consideration3. In our cohort, the proportion of 
children exposed to carbamazepine monotherapy with elevated scores (5.9%) was higher 
than the general population, and at a similar level to valproate monotherapy. 
Nevertheless, children exposed to polytherapy without valproate were most often 
exposed to carbamazepine and yet did not show elevated rates of autistic traits, and 
carbamazepine dose was unrelated to CARS scores. Thus, our data should be 
interpreted with caution and additional studies are required before changes in practice 
with regards carbamazepine in pregnant women should be considered.  
 
Autism spectrum disorders are highly heritable, with increased risk in first-degree 
relatives. People with ASD may also have seizures and there are epilepsy syndromes in 
which ASD is a prominent feature, yet the likelihood of inheriting ASD from a parent with 
epilepsy above and beyond population rates of inheritance is relatively less well 
understood. At interview, no mothers of children with elevated CARS scores reported a 
maternal or paternal family history of autism, although we did not screen parents to verify 
this.  Some children with elevated CARS scores had affected siblings who were not seen 
as part of the study, and this might be interpreted as familial risk. In all cases, however, 
mothers reported that the siblings were also exposed in utero, which suggests that AED 
exposure rather than ‘genetic susceptibility’ explains the occurrence of autism traits in 
those families. The different rates of elevated CARS scores across the AED exposure 
groups in our study suggest that maternal epilepsy per se does not account for autism 
traits in their offspring, and recent data from women with epilepsy who did not take AEDs 
during pregnancy found no evidence for elevated autism risk13. Genetic factors may 
mediate the association between valproate exposure and poor neurodevelopmental 
outcome and this may be dose-dependent and additional studies are required to clarify 
this.  
 
A number of other factors may influence the likelihood of a child meeting the criteria for 
ASD following in utero AED exposure. Some have speculated that increased use of 
maternal folate may be associated with rising ASD prevalence35. Our data, however, 
contradict this and in fact highlight the importance of folic acid supplementation in women 
with epilepsy, with an association between elevated CARS scores in children whose 
mothers did not report folic acid supplementation in the first trimester. We also found a 
clear association of maternal marijuana use during pregnancy and ASD symptoms in the 
children. These two factors should be included in preconceputal counselling and ante-
natal care discussions with women with epilepsy.  
 
The results of this study extend previous reports of increased rates of ASD following fetal 
valproate exposure7-9; 11; 12 by providing the first prospective assessment of all children in 
a cohort exposed to anticonvulsant medications in utero and controlling for confounding 
variables. These data are consistent with studies showing that autism-like behaviours can 
be seen in the offspring of pregnant rodents administered valproate10. Our findings 
support the concluding remarks of Bromley and colleagues11, that their study methods 
may have underestimated the risk of ASD risk in AED-exposed children. In addition to the 
younger age of their sample, almost a third of whom were below six years old, their study 
did not systematically assess ASD with an instrument such as the CARS, reducing the 
detection rates. The prevalence of autism traits in the Australian population when using 
the CARS is not known, so one interpretation of our findings is that our data simply reflect 
a greater sensitivity to ASD but poor specificity or poor diagnostic accuracy as a result of 
using this instrument in all cases. A recent systematic review of diagnostic and screening 
instruments for autism noted that any instrument with a diagnostic accuracy of 80 percent 
or more is equivalent to the “gold standard” of multi-disciplinary team diagnoses36; the 
CARS exceeds this threshold and has excellent levels of sensitivity and specificity. Thus, 
the current data raise the concern that many children exposed to AEDs in utero have 
undetected neurodevelopmental problems. Importantly, our sample differs from previous 
studies7-9; 11 in that we excluded children with major birth defects. There is strong 
evidence that fetal valproate exposure is associated with elevated rates of birth defects37, 
and that birth defects and autism often co-occur17. Our data suggest that there is an 
elevated risk of ASD independent of the presence of major birth defects and highlight the 
importance of continued monitoring of exposed children beyond infancy, particularly in 
those for whom initial surveillance is unremarkable.  
 
Sample size and selection bias are important factors to consider in observational cohort 
studies such as ours. The size of our individual groups was relatively small which may 
result in a misrepresentation of the risks associated with specific prenatal AED 
exposures. This would most likely occur if there was selection bias in our study. One 
potential source of bias in this study is the possibility that women who held concerns 
about their offspring were more likely to agree to participate. The study cut-off date 
precluded assessment in sixty-one percent of those approached about participation but 
not included in the study. Of the remaining group (14%) who declined to participate, the 
most common reason given was maternal concern about the child’s ability to cope with 
testing (anecdotally due to perceived educational or behavioural difficulties in the child).  
Mothers who did not agree to participate were similar to those included here on key 
epilepsy variables. The only characteristic that differed between participators and non-
participators was gestational age, with more preterm children amongst those who did not 
take part. Thus despite our relatively small overall and sub-groups’ sample size and the 
sampling method, the possibility of selection bias in favour of ASD seems unlikely to 
account for the results we report here. The number of children with elevated scores was 
relatively small compared to the overall sample. This might impact on analysis of 
confounding variables, although non-parametric analysis was used to mitigate against 
this risk.  
 
Another important potential confound is the impact of including in our analyses children 
with intellectual disability. The CARS was developed to distinguish between autism and 
neurodevelopmental delay due to other causes and as such performs well in low-
functioning children. Items rely most heavily upon the social and behavioural features of 
ASD and although some of our children performed poorly on IQ tests, their clinical 
presentation, captured by supra-threshold CARS scores, supports the contention that a 
higher-rate of ASD is associated with AED, particularly VPA, exposure in utero. Impaired 
social communication skills were often observed in the children in our study who did not 
already have a diagnosis of autism, suggesting that there is a broad behavioural 
phenotype that extends beyond cognitive impairment. Our data analyses excluded one 
child who enrolled in our outcomes study that had a previous diagnosis of ‘autistic traits’, 
yet his high level of function placed him well below the CARS cut-off, including that 
published recently for use in high-functioning ASD38. Including that child in our analyses 
would show that 11.5% (3/26) of VPA monotherapy exposed children had ASD. 
Accordingly, the current rate of ASD associated with prenatal AED exposure remains an 
estimate only; our study highlights the risk profile of this group of children and points to a 
need for ongoing prospective research in large samples of exposed children. 
 
There is considerable evidence emerging from these and other data that fetal valproate 
exposure is associated with increased risk of ASD. This under-recognised outcome has 
significant implications for clinical management of affected women. Women taking higher 
doses of valproate, particularly in polytherapy, have a greater risk of having an affected 
child. Valproate remains a highly efficacious drug for patients with primary generalised 
epilepsy and any decision to change or cease medication must be carefully weighed 
against the risks posed by inadequate seizure control to the mother or to the unborn 
child. In women of child-bearing age with epilepsy for whom the risk-benefit ratio is felt to 
favour continuing valproate treatment during pregnancy, the dose should be kept as low 
as possible to minimise the risk of the child having ASD in view of the strong associate 
between valproate dose and CARS found in this study. Many patients with genetic 
generalised epilepsy can be controlled with low dose valproate (<1000 mg/day), and in 
some this is the only treatment that can control the seizures. While low dose valproate 
treatment in pregnant women is free of the increased risk of ASD requires further 
investigation.   
 
Additional study of the link between ASD and fetal AED exposure is required to elucidate 
underlying mechanisms. In keeping with the elevated risk profile for children of women 
taking AEDs during pregnancy, especially those from lower socioeconomic groups, there 
is a need for research that focuses on early detection and early intervention for affected 
families. The potential for modifications of risk factors in women with epilepsy who 
become pregnant, including treatment modifications and lifestyle changes, to reduce the 
risk of their children having ASD39.  
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Key Points: 
• Prospective, blinded assessment of autism in children exposed prenatally to 
antiepileptic drugs reveals increased risk relative to population rates 
• Children of mothers who took valproate in combination with other antiepileptic 
drugs are at greatest risk of autism 
• There is a dose-response relationship between valproate monotherapy and autism 
risk 
• Additional data on the neurodevelopmental risk associated with low-dose prenatal 
valproate exposure are required.  
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Table 1: Maternal characteristics by drug exposure group 
 Maternal IQ 
(Mean(SD)) 
(range) 
Age at seizure 
onset (years) 
Epilepsy 
onset type 
(Generalised/ 
Partial) 
Seizures 
during 
pregnancy 
(No/Yes) 
Pregnancy 
duration 
(weeks) 
Child IQ 
VPA (Mono) (N=26) 105.9 (12.8)  
83-129 
15.6 (6.6) 
5-31 
21G/5P 20N/6Y 39.4 (1.8) 
34-42 
95.8 (13.3) 
66-117 
       
VPA (Poly) (N=15) 91.7 (14.8) 
65-120 
11.4 (7.5)  
1-28 
11G/4P 3N/12Y 39.3 (3.1) 
29-41 
81.0 (17.5) 40-
103 
      
CBZ (Mono) (N=34) 108.7 (12.3) 
81-129 
16.8(10.1) 
0-32 
7G/23P/4UK 22N/12Y 39.3 (1.4) 
36-41 
100.7 (14.3) 
71-126 
      
‘Other’  
Non-VPA poly (N=19) 
 
      
102.3 (14.3)  
72-123 
12.9 (7.4) 0.5-28 5G/13P/1UK 9N/10Y 39.4 (1.0) 
38-41 
93.8 (10.6) 
72-110 
 
LTG mono (N=9) 
 
 
Other mono* (N=2) 
109.3 (8.1) 
99-119 
 
109.5 (38.9) 
109-110 
23.3 (10.3) 
1-36 
 
 
16.0 (8.5) 
10-22 
2G/7P 
 
 
 
2P 
4N/5Y 
 
 
 
1N/1Y 
39.8 (1.7) 
38-42 
 
 
38.5 (0.7) 
38-39 
105.1 (5.7) 
95-115 
 
 
96.0 (32.5) 
73-119 
* One each topiramate, gabapentin. Key: VPA=valproate; LTG=lamotrigine; CBZ=carbamazepine 
 
 
  
Table 2: Polytherapy drug combinations in the sample 
 
Polytherapy combinations Frequency Percentage 
Including Valproate    
VPA + CBZ 1 6.7 
VPA + CBZ + CLON 1 6.7 
VPA + CBZ + LTG + CLON 1 6.7 
VPA + CLON 2 13.3 
VPA + LEV 1 6.7 
VPA + LTG 6 40 
VPA + LTG + CLON  1 6.7 
VPA + LTG + ETH 1 6.7 
VPA + TIAG 1 6.7 
Total (15) (100) 
Without valproate    
CBZ + CLON 3 15.8 
CBZ + CLON + VIG + GAB 1 5.3 
CBZ + LTG 5 26.3 
CBZ + PHEN 3 15.8 
CBZ + VIG 1 5.3 
CLON + CBZ 1 5.3 
CLON + PHEN  1 5.3 
LTG + PHEN 2 10.5 
LTG + PHEN + VIG  1 5.3 
LTG + TOP 1 5.3 
Total (19) (100) 
Key: VPA=valproate; CBZ=carbamazepine; CLON=clonazepam; LTG=lamotrigine; LEV=levetiracetam; ETH=ethosuximide; 
TIAG=tiagabine; VIG=vigabatrin; PHEN=phenytoin; TOP=topiramate 
 
  
Table 3. Rates of elevated CARS scores 
 
 CARS>3
0 
CARS 
27-29 
Total 
Valproate  
(Monotherapy) 
1/26 1/26 2/26 
3.8% 3.8% 7.7% 
Valproate  
(Polytherapy) 
6/15 1/15 7/15 
40.0% 6.7% 46.7% 
Carbamazepine  
(Monotherapy) 
1/34 1/34 2/34 
2.9% 2.9% 5.9% 
Other  
(Mono / 
Polytherapy) 
0/30 0/30 0/30 
0.0% 0.0% 0.0% 
Total 8/105 3/105 11/105 
7.6% 2.9% 10.5% 
 
 
 
 
Table 4. Maternal Pregnancy History for Children with Autism Spectrum Disorders or Autistic traits 
 
Case ASD Details Child IQ Antiepileptic 
Drug(s) 
Daily Dose 
(range across 
pregnancy)1 
Other Drug(s)  Folic 
Acid 2 
Family 
History of 
ASD 
1 Autism3 
(CARS=35) 
66 Valproate  3000mg Tobacco (25 
cigarettes/day) 
Marijuana (3 
joints/week) 
Alcohol (2-5 
units/day until 12 
weeks) 
500mcg 
daily AC 
No 
2 Autism3 
(CARS=32.5) 
78 Valproate 
Levetiracetam 
1200mg 
2000mg 
Tobacco (>30 
cigarettes/day) 
Alcohol (<1 
unit/day) 
400mcg 
daily BC 
No 
3 Autism3 
(CARS=33) 
82 Carbamazepine 600-800mg Paroxetine (dose 
not specified; until 
12 weeks) 
None No 
4 PDD-NOS3 
(CARS=38.5) 
61 Valproate 
Clonazepam 
2500mg 
0.5mg 
None 10mg 
daily BC 
No 
5 CARS=50; 40 Clonazepam 0.5mg (until Tobacco (<10 5mg No 
Intellectual & 
language 
delay; Socially 
unresponsive. 
Valproate 21 weeks) 
200-400mg 
(from 21 
weeks) 
cigarettes/day) 
Marijuana (3 
joints/day until 12 
weeks) 
daily BC 
64 CARS=37; 
Intellectual & 
language 
delay; Social 
difficulties. 
80 Valproate 
Lamotrigine 
3000mg 
100mg 
None None Sibling  
(Case 7) 
74 CARS=30; 
Intellectual & 
language 
delay; Social 
difficulties. 
64 Valproate 
Lamotrigine 
Ethosuximide 
2500- 3000mg 
50-200mg 
500mg (until 4 
weeks) 
None 5mg 
daily BC 
Sibling  
(Case 6) 
8 CARS=34.5; 
Intellectual & 
language 
delay; Social 
difficulties. 
67 Valproate 
Lamotrigine 
1000mg 
400mg (until 
12 weeks) 
Alcohol (<1 
unit/week) 
5mg 
daily BC 
Sibling with 
similar 
problems4  
9 CARS=29; 
Language 
delay; Social 
difficulties. 
92 Lamotrigine 
Valproate 
400mg 
300mg (from 
29 weeks) 
None 5mg 
daily BC 
Sibling with 
autism5  
10 CARS=28; 
Language 
75 Valproate 1000-1500mg Diclofenac 
potassium 
500mcg No 
delay; Social 
difficulties. 
(irregular from 28 
weeks) 
daily AC 
11 CARS=27.5; 
ADHD1; 
Learning & 
social 
difficulties 
96 Carbamazepine 1200mg None 5mg 
daily BC 
Sibling with 
Asperger’s5 
1 Where one value is given, the dose was unchanged across pregnancy 
2 AC=Commenced after conception; BC = Commenced before conception 
3 Previously diagnosed 
4 Cases 6 and 7 were siblings 
5 By parental report; child was not seen because they were outside the study age range. All three siblings were 
also AED-exposed
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delay; Social 
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weeks) 
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Learning & 
social 
difficulties 
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Table 5. Predictors of CARS Scores in linear regression 
 
 
Variable B Coefficient  
(Std. Error) 
t (p) 
Mean valproate dose 0.002 (0.001) 3.20 (.002) 
Folic Acid 1st Trimester  -8.631 (2.830) -3.05 (.003) 
Marijuana Use 14.844 (2.88) 5.16 (<.001) 
Mean carbamazepine dose 0.000 (0.001) -0.07 (.945) 
Polytherapy  1.727 (1.126) 1.53 (.128) 
Seizure(s) During Pregnancy  0.963 (1.013) 0.95 (.345) 
Maternal IQ 0.000 (.044) 0.007 (.994) 
Socioeconomic status -0.014 (0.027) -0.52 (.607) 
Constant 25.831 (5.007) 5.16 (<.001) 
 
 
